Olema Pharmaceuticals, Inc. (NasdaqGS: OLMA)
Health Care · Biotechnology · US
$11.20
+4.77% today · +91.2% 1Y
Olema Pharmaceuticals, Inc. (NasdaqGS: OLMA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $935.35M and employs 137 people.
Over the last twelve months the share price has gained 91.2%, trading between 5.36 and 36.26.
Tweenvest scores Olema Pharmaceuticals, Inc. across four factors: quality 28/100. Its strongest factor is quality.
OLMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $935.35M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.13
- Dividend yield
- —
- Beta (5Y)
- 2.01
- 52-week high
- $36.26
- 52-week low
- $5.36
- Avg volume (3M)
- —
- Shares outstanding
- 87.50M
- Employees
- 137
- Next earnings
- —
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
- ISIN
- US68062P1066
- Founded
- 2006
- Listed since
- Nov 19, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.72 | +0.35% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $445.50 | +0.74% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.50 | -0.21% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.